[{"data":1,"prerenderedAt":134},["ShallowReactive",2],{"drug-lotilaner-eye":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":33,"contraindications":58,"warnings":59,"renal":60,"monitoring":61,"interactions":62,"review":63,"examples":66,"atc":72,"iran":74,"usApproval":81,"links":87,"populations":98},"lotilaner-eye",1,{"fa":7,"en":8},"قطره چشمی لوتیلانر (بلفاریت دمودکسی)","Lotilaner eye drops (Demodex blepharitis)","sensory-organs",{"fa":11,"en":12},"ضدانگل چشمی","Ophthalmic antiparasitic",[14],{"name":15,"market":16},"Xdemvy","US",[18,19],"xdemvy","لوتیلانر",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":28,"refs":29},"sol","eye-drops","ophthalmic","Lotilaner 0.25% eye drops",{"amount":5,"unit":27,"perUnit":27},"drop",[16],[30],{"source":31,"section":32},"fda-xdemvy","3",[34],{"id":35,"disease":36,"label":37,"population":40,"type":41,"unit":27,"dose":42,"refs":44,"durationDays":47,"notes":49},"demodex","blepharitis",{"fa":38,"en":39},"بلفاریت دمودکسی — یک قطره در هر چشم دو بار در روز، ۶ هفته","Demodex blepharitis — 1 drop in each eye twice daily, 6 weeks",{},"fixed",{"perDose":5,"dosesPerDay":43},2,[45],{"source":31,"section":46},"2",{"min":48,"max":48},42,[50],{"text":51,"refs":54},{"fa":52,"en":53},"حدود ۱۲ ساعت فاصله؛ با سایر قطره‌ها ۵ دقیقه فاصله. لنز تماسی قبل از قطره درآورده و ۱۵ دقیقه بعد گذاشته شود.","About 12 h apart; 5 min from other drops. Remove contact lenses and reinsert after 15 min.",[55,56],{"source":31,"section":46},{"source":31,"section":57},"5.2",[],[],[],[],[],{"status":64,"reviewer":65,"date":65},"unverified",null,[67],{"regimen":35,"formulation":22,"input":68,"expect":71},{"ageYears":69,"weightKg":70},50,70,{"perDose":5,"dosesPerDay":43},[73],"S01AX25",{"status":75,"refs":76},"not-found",[77],{"source":78,"section":79,"url":80},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Lotilaner%20eye%20drops",{"kind":82,"refs":83,"id":86},"NDA",[84],{"source":31,"section":85},"SPL approval \u002F marketing category","NDA217603",[88,91,95],{"kind":89,"url":90,"label":86},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=217603",{"kind":92,"url":93,"label":94},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=ccd9e37c-654e-4e84-8c85-6523457df979","FDA Xdemvy",{"kind":96,"url":97,"label":73},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=S01AX25",{"pregnancy":99,"lactation":108,"pediatric":116,"geriatric":125},{"level":100,"text":101,"quote":104,"refs":105},"caution",{"fa":102,"en":103},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no available data on XDEMVY use in pregnant women to inform any drug associated risk; however, systemic exposure to lotilaner from ocular administration is low [see Clinical Pharmacology (12.3) ] .",[106],{"source":31,"section":107},"8.1",{"level":100,"text":109,"quote":112,"refs":113},{"fa":110,"en":111},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of XDEMVY in human milk, the effects on the breastfed infant, or the effects on milk production.",[114],{"source":31,"section":115},"8.2",{"level":117,"text":118,"quote":121,"refs":122},"not-established",{"fa":119,"en":120},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients below the age of 18 years have not been established.",[123],{"source":31,"section":124},"8.4",{"level":126,"text":127,"quote":130,"refs":131},"ok",{"fa":128,"en":129},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness have been observed between elderly and other adult patients.",[132],{"source":31,"section":133},"8.5",1792115186893]